Some dont show any symptoms, while others cause symptoms to appear
In the pharmaceutical sector, Otsuka has made several significant acquisitions and partnerships
Glucagon-like peptide-1 receptor (GLP-1) agonists are an effective treatment for controlling blood glucose levels in people with type 2 diabetes, particularly those who do not respond, or stop responding to, first-line treatments, such as There are many versions of GLP-1 drugs, including: liraglutide(Victoza), which people inject daily semaglutide (Rybelsus), an oral tablet which people take once daily dulaglutide(Trulicity), which people inject once a week semaglutide (Ozempic/ Wegovy), which people inject once a week exenatide(Bydureon), which people inject once a week
Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin
Faster is not better and it raises your side-effect risk